Nuveen LLC Takes $1.22 Million Position in Cytek Biosciences, Inc. $CTKB

Nuveen LLC purchased a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 304,985 shares of the company’s stock, valued at approximately $1,223,000. Nuveen LLC owned approximately 0.24% of Cytek Biosciences as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in CTKB. CenterBook Partners LP purchased a new position in shares of Cytek Biosciences in the first quarter valued at $3,390,000. Millennium Management LLC grew its position in Cytek Biosciences by 321.8% during the fourth quarter. Millennium Management LLC now owns 803,923 shares of the company’s stock worth $5,217,000 after buying an additional 613,314 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Cytek Biosciences during the fourth quarter worth about $2,527,000. Acuitas Investments LLC purchased a new position in Cytek Biosciences during the first quarter worth about $1,328,000. Finally, Dimensional Fund Advisors LP grew its position in Cytek Biosciences by 16.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,830,432 shares of the company’s stock worth $11,880,000 after buying an additional 262,607 shares in the last quarter. 69.46% of the stock is currently owned by hedge funds and other institutional investors.

Cytek Biosciences Stock Down 0.7%

Shares of CTKB stock opened at $4.14 on Monday. The business has a 50-day moving average price of $3.68 and a two-hundred day moving average price of $3.72. Cytek Biosciences, Inc. has a 12-month low of $2.37 and a 12-month high of $7.63. The firm has a market cap of $526.69 million, a P/E ratio of -82.80 and a beta of 1.36.

Analyst Ratings Changes

Several equities analysts recently commented on CTKB shares. The Goldman Sachs Group reduced their target price on Cytek Biosciences from $3.50 to $3.00 and set a “sell” rating for the company in a research report on Monday, May 12th. TD Cowen cut Cytek Biosciences from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a research report on Friday, May 9th. Finally, Morgan Stanley reduced their target price on Cytek Biosciences from $9.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 28th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $5.60.

Cytek Biosciences Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.